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severe adult respiratory distress syndrome
undergoing extracorporeal membrane
oxygenation therapy: a retrospective study
Stephanie Klinzing1*, Urs Wenger2, Peter Steiger1, Christoph Thomas Starck3, Markus Wilhelm3, Reto A Schuepbach1
and Marco Maggiorini2
Abstract
Introduction: This study was designed as an external validation of the recently proposed Predicting Death for
Severe ARDS on V-V ECMO (PRESERVE) score, The respiratory extracorporeal membrane oxygenation survival
prediction (RESP) score and a scoring system developed for externally retrieved patients on extracorporeal membrane
oxygenation (ECMO) at our institution. All scores are proposed for the estimation of survival probability after ECMO
treatment for severe adult respiratory distress syndrome.
Methods: Data from 51 patients (2008 to 2013) were analyzed in this retrospective single-center study. A calculation of
an adapted PRESERVE score, the RESP score as well as the score developed for externally retrieved ECMO patients was
performed.
Results: Seventy one percent of patients received veno-venous (v-v) and 29% venous-arterial (v-a) ECMO support
during the study period. Overall survival at 6 months was 55%, with a 61% survival rate for v-v cannulated patients and
a 40% survival rate for v-a cannulated patients. The PRESERVE score discriminated survivors and non-survivors with an
area under the curve of 0.67 (95% CI 0.52 to 0.82, P = 0.03). Analyzing survival prediction according to cannulation
modus, the PRESERVE score and the RESP score significantly predicted survival for patients on v-v ECMO with an area
under the curve of 0.75 (95% CI 0.57 to 0.92, P = 0.01) and 0.81 (95% CI 0.67 to 0.95, P = 0.035), respectively, while the
scoring system developed for externally retrieved ECMO patients failed to predict survival in our study population.
All scores failed to predict mortality for patients on v-a ECMO.
Conclusion: Our single-center validation confirms that the proposed PRESERVE and RESP score predict survival for
patients treated with v-v ECMO for severe adult respiratory distress syndrome.
Introduction
Adult respiratory distress syndrome (ARDS) still has
mortality rates between 45 and 55% [1]. Therapy re-
mains supportive, with a proven survival benefit for lung
protective ventilation [2] and prone positioning [3]. Des-
pite advanced supportive procedures, including high-
frequency ventilation, nitric oxide (NO) inhalation and
steroids, a subgroup of patients remains severely hypox-
emic [4].
Extracorporeal membrane oxygenation (ECMO) sup-
port as a rescue therapy has gained renewed interest since
the encouraging, though debated, results of the CESAR
trial [5] and favorable outcome in A(H1N1) influenza-
induced ARDS [6].
Since ECMO therapy requires highly specialized staff and
equipment, an appropriate selection of patients stratified
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by outcome prediction for this economically costly ther-
apy would be of great interest. This approach has been ad-
dressed by Pappalardo and colleagues who developed the
ECMOnet score concerning risk stratification in H1N1
pneumonia [7] and Lindskov and colleagues who devel-
oped a score concerning ICU survival [8]. Recently, the
question of 6-month outcome prediction and risk stratifi-
cation of ARDS patients treated by ECMO was addressed
by Schmidt and colleagues, who developed the Predicting
Death for Severe ARDS on VV-ECMO (PRESERVE) score
[9]. This mortality risk score was developed with eight
pre-ECMO parameters; that is, age, body mass index, im-
munocompromised status, prone position, days of mech-
anical ventilation, sepsis-related organ failure assessment
(SOFA), positive end-expiratory pressure (PEEP), and plat-
eau pressure. Recently, the same group developed the
Respiratory Extracorporeal membrane oxygenation Sur-
vival Prediction (RESP) score addressing the question of
survival prediction after ECMO for severe acute respiratory
failure [10]. Twelve pre-ECMO parameter were incor-
porated in this more complex score, where the acute re-
spiratory diagnosis, central nervous dysfunction, acute
associated non-pulmonary infection, neuromuscular block-
ade agents, use of NO, bicarbonate infusion, cardiac arrest,
partial pressure of carbon dioxide (PaCO2) and peak in-
spiratory pressure are used in addition to age, immuno-
compromised status and days of mechanical ventilation.
Roch and colleagues [11] recently developed a simple
score based on age, SOFA and diagnosis of influenza
pneumonia for outcome prediction of ARDS patients
selected for retrieval by a mobile ECMO team. The aim
of the present study was to conduct an external valid-
ation of the PRESERVE score [9], the RESP score [10]
and the score developed by Roch and colleagues [11] to
investigate their usefulness in predicting survival in a
single ECMO center.
Material and methods
Study design and objectives
All consecutive ARDS patients who received ECMO
therapy in the ICUs of the University Hospital of Zurich
between 1 January 2008 and 31 March 2013 were
included.
Patients
Criteria for ECMO were standardized according to local
guidelines. ECMO therapy was evaluated for patients
with severe but potentially reversible respiratory failure
with persistent hypoxemia or hypercapnea. This was de-
fined as a Horowitz index (PaO2/FiO2) <70 mmHg with
FiO2 > 0.8 and/or pH <7.2 despite optimized mechanical
ventilation (PEEP ≥10 cmH2O, tidal volume 6 ml/kg body
weight) and possible use of adjunctive therapy such as
NO, prone position, kinetic therapy and extracorporeal
carbon dioxide removal systems. Case selection of patients
with preceding mechanical ventilation of more than 7 days
duration, high pressure (peak inspiratory pressure >30
cmH2O), FiO2 > 0.8 and patients over 65 years of age was
performed based on the clinical opinion of the ECMO
consultants.
Contraindications for ECMO therapy were age >75 years,
pH <6.8, potassium >10 mmol/l, malignancies with fatal
prognosis within 5 years, intracranial pathology or any
other contraindication for therapeutic anticoagulation
or patients with the decision for limitation of therapeutic
interventions.
ECMO was performed primarily in a veno-venous (v-v)
configuration. Veno-arterial (v-a) cannulation was chosen
in selected patients when v-v ECMO was anticipated to be
not sufficient enough, such as in cases of moderate to
severe heart failure, severe hypoxemia, hemodynamic
instability or pulmonary hypertension.
All v-v ECMO was performed with percutaneous
cannulation. The standard configuration for v-v ECMO
was femoro-jugular, and for v-a ECMO it was femoro-
subclavian. An end-to-side anastomosis onto the right
subclavian artery was made with an 8-mm vascular pros-
thesis and the cannula placed inside the graft. Circuit
configuration was as follows: FemFlex cannula (Edwards
Lifescience, Irvine, California, USA), heparin-coated tub-
ing (Bioline, Maquet, Hirrlingen, Germany), ROTAFLOW
centrifugal pumps (Maquet) and Quadrox PLS oxygen-
ator with heater unit HU 35 (both Maquet).
Data collection
We collected baseline demographic characteristics as
well as physiologic and respiratory data immediately
prior to initiation of ECMO therapy. Ventilation therapy
and the use of precedent adjunctive therapy were noted.
Data for hospital and ICU admission (local ICU and re-
ferral to ECMO center ICU) as well as the onset of
mechanical ventilation were recorded. Laboratory data
closest to the initiation of ECMO therapy were noted.
Data for hospital survival and 6-month survival after
ICU discharge were collected.
The PRESERVE score, RESP score and score according
to Roch and colleagues were calculated according to the
original papers [9-11] (Tables 1, 2 and 3). While the
PRESERVE score was proposed for the risk estimation
of death 6 months after ICU discharge for ARDS pa-
tients treated on ECMO, the RESP score and the score
proposed by Roch and colleagues were developed for
prediction of hospital mortality. Since plateau pressure
(incorporated in the PRESERVE score) is not routinely
determined in pressure-controlled ventilation in our
institution, the PRESERVE scoring was adapted - peak
inspiratory pressure expressing dynamic compliance was
used as a surrogate for plateau pressure.
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The PRESERVE score [9] was originally defined for
patients mainly treated on v-v ECMO (95%). Since v-a
cannulation was applied in 29% of patients at our insti-
tution during the study period, an additional separate
analysis of patients on v-v ECMO and v-a ECMO was
chosen for better comparability of data. The same ap-
proach was chosen for the RESP score [10]. Only six pa-
tients in our study were initiated on ECMO in a referring
hospital by a mobile ECMO team. Therefore, the score as
proposed by Roch and colleagues [11] was applied for the
whole study group.
This retrospective analysis was approved by the Kanto-
nale Ethikkommission Zurich (KEK-ZH-Nr.2014-0318)
which waived the need for informed consent for the
study period.
Statistical analysis
Data were tested for normal distribution using the
Kolmogorov-Smirnov and Shapiro-Wilk tests. Continu-
ous variables were analyzed using the Student’s t-test or
Mann-Whitney U test as appropriate. Categorical vari-
ables were compared using Pearson’s Chi Square test or
Fisher’s exact test as appropriate. All P values were two-
sided and considered statistically significant if P ≤ 0.05.
The cut-off value of 35 cmH2O for peak inspiratory pres-
sure was determined by receiver operating curve (ROC)
analysis and Yuden’s index (data not shown).
The discriminative performance of the calculated
scores was evaluated by ROC analysis.
Statistical analysis was performed using SPSS Statistics
version 22 (IBM, Chicago, IL, USA).
Results
During the study period a total of 59 patients suffering
from severe ARDS received ECMO therapy. Due to
incomplete data sets, 51 patients were eligible for ana-
lysis; of these, 36 patients (71%) underwent v-v ECMO
support and 15 patients (29%) underwent v-a ECMO
support. V-v ECMO was performed as femoro-jugular
cannulation in 72% of cases, while 28% were cannu-
lated bifemorally. V-a ECMO was performed as femoro-
subclavian cannulation in 60% of cases, while 40% were
cannulated femoro-femoral.
Table 1 PRESERVE score parameters [9]
Parameter Points
Age (years) <45 0
45-55 2
>55 3
Body mass index >30 kg/m2 −2
Immunocompromiseda 2
Mechanical ventilation >6 days 1
SOFA >12 1
No prone positioning before ECMO 1
PEEP <10 cmH2O 1
Peak inspiratory pressureb >35 cmH2O 1
aDefined as hematological malignancy, solid tumor, solid organ transplantation,
high-dose or long-term corticosteroid and/or immunosuppressant use or HIV
infection. bOr plateau pressure >30 cmH2O = 1 point as proposed by Schmidt and
colleagues [9]. ECMO, extracorporeal membrane oxygenation; PEEP, positive
end-expiratory pressure; PRESERVE, Predicting Death for Severe ARDS on
VV-ECMO; SOFA sepsis-related organ failure assessment.
Table 2 RESP score parameters [10]
Parameter Score
Age (years)
18-49 0
50-59 −2
≥60 −3
Immunocompromised statusa −2
Mechanical ventilation prior to initiation of ECMO
<48 hours 3
48 hours to 7 days 1
>7 days 0
Acute respiratory diagnosis group (select only one)
Viral pneumonia 3
Bacterial pneumonia 3
Asthma 11
Trauma and burn 3
Aspiration pneumonitis 5
Other acute respiratory diagnoses 1
Nonrespiratory and chronic respiratory diagnoses 0
Central nervous system dysfunctionb −7
Acute associated (nonpulmonary) infectionc −3
Neuromuscular blockade agents before ECMO 1
Nitric oxide use before ECMO −1
Bicarbonate infusion before ECMO −2
Cardiac arrest before ECMO −2
PaCO2 (mmHg)
<75 0
≥75 −1
Peak inspiratory pressure (cmH2O)
<42 0
≥42 −1
Total score −22 to 15
aImmunocompromised is defined as hematological malignancies, solid tumor,
solid organ transplantation, human immunodeficiency virus, and/or cirrhosis.
bCentral nervous system dysfunction diagnosis combined neurotrauma, stroke,
encephalopathy, cerebral embolism, and seizure and epileptic syndrome.
cAcute associated (nonpulmonary) infection is defined as another bacterial,
viral, parasitic, or fungal infection that did not involve the lung. An online
calculator is available at [18]. ECMO, extracorporeal membrane oxygenation;
PaCO2, partial pressure of carbon dioxide; RESP, Respiratory ECMO
Survival Prediction.
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Overall 6-month survival was 55% (95% CI 44 to 74%).
Analyzing survival according to cannulation modus, v-v
cannulated patients had a 6-month survival of 61% (95%
CI 45 to 75%) while survival for v-a cannulated patients
was 40% (95% CI 20 to 64%). This difference was not
statistical significant (P = 0.22).
Patient baseline characteristics are presented in Table 4.
Overall, the leading cause of ECMO implantation was
bacterial infection followed by influenza and primary
ARDS. Comorbidities as expressed by Charlson’s score
[12] were more severe in the non-survivor group (P = 0.03),
while age (P = 0.05) as well as the other tested variables
did not reveal any statistically significant difference. Com-
paring baseline characteristics according to v-v or v-a
cannulation modus did not reveal any difference between
groups (see Additional file 1).
Clinical and respiratory characteristics at ECMO initi-
ation are presented in Table 5. Overall, time intervals
between hospital admission and referral to the ECMO
Table 3 Hospital mortality score proposed by Roch and
colleagues [11]
Parameter Points
SOFA
<9 0
9-11 1
≥12 2
Age (years)
<45 0
≥45 1
Influenza pneumonia
Yes 0
No 1
Total score 0-4
ECMO, extracorporeal membrane oxygenation; SOFA, sequential organ failure
assessment.
Table 4 Baseline characteristics of all ECMO-treated ARDS patients according to survival status 6 months post-ICU
discharge
Characteristic All patients (n = 51) Status 6 months post-ICU P value
Alive (n = 28) Dead (n = 23)
Age (years) 48 (33-58) 42 (31-53) 56 (38-60) 0.05
Men 27 (53) 16 (57) 11 (48) 0.35
Body mass index (kg/m2) 25 (22-29) 26 (23-29) 24 (20-32) 0.36
Charlson score 2 (1-4) 1 (1-4) 4 (2-5) 0.03
SAPS II 48 (30-61) 43 (29-56) 51 (39-67) 0.09
SOFA score 12 (9-13) 11 (9-13) 12 (9-15) 0.09
Chronic lung disease 8 (16) 4 (14) 4 (17) 0.76
Pregnant or postpartum 0 (0) 0 (0) 0 (0) 1.0
Diabetes mellitus 7 (14) 3 (11) 4 (17) 0.69
Renal insufficiency 4 (8) 3 (11) 1 (4) 0.62
Immunocompromiseda 17 (33) 7 (25) 10 (44) 0.23
Hematological malignancies 4 (8) 3 (11) 1 (4) 0.32
Solid tumor 4 (8) 1 (4) 3 (13) 0.32
Solid organ transplantation 3 (6) 2 (7) 1 (4) 0.67
High-dose or long-term CS/IS 9 (18) 4 (14) 5 (22) 0.49
HIV 3 (6) 2 (7) 1 (4) 0.67
ARDS etiology 0.27
Peri-/postoperative 5 (10) 3 (11) 2 (9)
Influenza A H1N1 8 (16) 2 (7) 6 (26)
Influenza other 7 (14) 3 (11) 4 (17)
Bacterial infection 21 (41) 13 (47) 8 (35)
Primary ARDS 8 (16) 5 (18) 3 (13)
Others 3 (6) 2 (7) 1 (4)
Values are expressed as median (interquartile range) or n (%). aImmuncompromised status included hematological malignancies, solid tumors, solid-organ
transplantation, high-dose or long-term corticosteroids and/or immunosuppressant use, or HIV infection. ARDS, acute respiratory disease syndrome; CS/IS,
corticosteroids or immunosuppressants; ECMO, extracorporeal membrane oxygenation; SAPS, simplified acute physiology score; SOFA, sepsis-related organ
failure assessment.
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center (P = 0.046), hospital admission and ECMO im-
plantation (P = 0.03), and ICU admission and ECMO
implantation (P = 0.03) showed a significant difference
between survivors and non-survivors. The same time
intervals remained statistically significant in the sub-
analysis of patients receiving v-v ECMO: non-survivors
had a longer time interval between hospital admission and
ECMO center referral (median 2 days (interquartile range
(IQR) 1-4) versus median 8 days (IQR 7-12), P = 0.04), a
longer time interval between hospital admission and
ECMO implantation (median 4 days (IQR 2-8) versus
12 days (IQR 8-15), P < 0.001) and longer time interval be-
tween ICU admission and ECMO implantation (median
3 days (IQR 1-6) versus 8 days (IQR 7-11), P = 0.002). In
the v-v group, the duration of mechanical ventilation
before ECMO initiation was significantly longer in the
non-survivor group (median 1 day (IQR 1-6) versus me-
dian 8 days (IQR 2-10), P = 0.02). In the v-a ECMO group,
no difference between survivors and non-survivors could
be detected. Comparing v-v and v-a cannulated patients,
all collected parameters did not show any statistical sig-
nificance between groups (see Additional file 2).
The distribution of patients into groups according to
the criteria of the PRESERVE and RESP groups, as well as
by the score of Roch and colleagues, is presented in
Tables 6, 7 and 8; ROC analysis of the scores is presented
in Table 9. Data concerning the survival probabilities ac-
cording to the various scores are presented in Table 10.
Overall, the PRESERVE score significantly discrimi-
nated survivors and non-survivors with an area under
Table 5 Clinical and ventilation characteristics at the time of ECMO initiation according to survival status
Characteristic All patients (n = 51) Status 6 months post-ICU P value
Alive (n = 28) Dead (n = 23)
Ventilation parameters
PaO2/FiO2 57 (49-74) 55 (44-67) 64 (52-82) 0.049
FiO2 100 (100-100) 100 (100-100) 100 (100-100) 0.99
PEEP (cmH2O) 12 (10-15) 13 (10-15) 12 (10-15) 0.73
Tidal volume (ml/PBW kg) 8 (5-8) 7 (5-8) 8 (5-9) 0.51
Respiratory rate (per minute) 28 (24-33) 30 (24-36) 26 (23-31) 0.20
Peak inspiratory pressure (cmH2O) 34 (31-37) 33 (31-37) 34 (29-37) 0.70
Pre-ECMO blood gases
pH 7.27 (7.12-7.35) 7.24 (7.11-7.31) 7.29 (7.15-7.37) 0.33
PaO2 (mmHg) 57 (49-73) 55 (44-67) 63 (52-74) 0.20
PaCO2 (mmHg) 57 (47-76) 57 (48-76) 58 (47-76) 0.85
HCO3
− (mmol/l) 24 (18-29) 24 (19-29) 23 (18-29) 0.88
SaO2 (%) 86.6 (78.0-92.7) 87 (76-93) 86 (82-92) 0.80
Lactate arterial (mmol/l) 1.6 (0.7-2.9) 1.6 (0.9-2.8) 1.6 (0.7-3.0) 0.75
Rescue therapy
Prone positioning 9 (18) 3 (11) 6 (26) 0.27
Nitric oxide 26 (51) 15 (54) 11 (48) 0.78
Bilateral infiltration 48 (94) 27 (96) 21 (91) 0.58
Pre-ECMO steroids 23 (45) 11 (39) 12 (52) 0.41
Pre-ECMO vasopressors 46 (90) 25 (89) 21 (91) 0.81
Pre-ECMO pneumothorax 6 (12) 2 (7) 4 (17) 0.39
Mobile ECMO team 6 (12) 3 (11) 3 (13) 0.80
Interval (days)
Hospital to ICU admission 1 (0-3) 1 (0-3) 1 (0-4) 0.89
Hospital to ECMO center admission 4 (1-8) 2 (1-6) 7 (4-10) 0.046
Hospital admission to ECMO 7 (4-13) 4 (2-13) 9 (6-14) 0.03
ICU admission to ECMO 4 (1-8) 3 (1-6) 7 (3-10) 0.03
MV to ECMO 2 (1-8) 1 (1-6) 4 (1-10) 0.14
Values are expressed as median (interquartile range) or n (%). ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; HCO3
–, bicarbonate;
MV, mechanical ventilation; PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; PBW, predicted body weight; PEEP, positive end-expiratory
pressure; SaO2, oxygen saturation.
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the curve (AUC) of 0.67 (95% CI 0.52 to 0.82; P = 0.03).
Survival when subdivided into groups according to the
PRESERVE score is presented in Figure 1. For patients
on v-a ECMO the PRESERVE score failed to predict sur-
vival (P = 0.96). The PRESERVE score showed the best
performance for patients on v-v ECMO (AUC = 0.75,
95% CI 0.57 to 0.92; P = 0.01). The RESP score perfor-
med similarly, with an AUC of 0.65 (95% CI 0.5 to 0.8)
for all patients and the best performance for v-v cannu-
lated patients (AUC = 0.81, 95% CI 0.67 to 0.95), but
it was only statistically significant for the v-v group
(P = 0.035).
Applying the scoring method developed by Roch and
colleagues [11] for the whole study group did not discrim-
inate between survivors and non-survivors (AUC= 0.55,
95% CI 0.38 to 0.71; P = 0.57).
Discussion
This study is a retrospective analysis of 51 patients
requiring ECMO support for severe ARDS in our insti-
tution, testing the recently proposed PRESERVE [9] and
RESP [10] scores as well as the score developed by Roch
and colleagues [11] for outcome prediction of ARDS
patients treated on ECMO. The objective was to test the
usefulness of these scoring systems for future identifica-
tion of those ARDS patients likely to profit from ECMO
therapy. The results indicate that both the PRESERVE
score and the RESP score are of help identifying those
patients suitable for ECMO therapy.
Comparing our baseline patients characteristics to
Schmidt and colleagues [9,10] with respect to parameters
incorporated in the PRESERVE score calculation, patients
were comparable concerning age, body mass index, SOFA
score, days of mechanical ventilation before ECMO and
PEEP, while the incidence of immunocompromised pa-
tients and use of prone positioning before ECMO was
lower in our study population. The lower incidence of
prone positioning affects the score calculation by yielding
higher scores and should be borne in mind when translat-
ing our findings into the clinic. We substituted the score
by peak inspiratory pressure for plateau pressure score due
to ventilation using the pressure-controlled mode (BiPAP®;
Draeger, Lübeck, Germany) prior to ECMO implantation
(peak pressure ≥35 cmH2O= 1 point).
Despite finding a similar PaO2/FiO2 ratio to Schmidt
and colleagues [9], patients in our study were ventilated
Table 6 PRESERVE groups for all patients and according to the type of cannulation, either veno-venous or veno-arterial
ECMO
PRESERVE
group
Veno-venous and veno-arterial ECMO Veno-venous ECMO Veno-arterial ECMO
All
patients
(n = 51)
Status 6 months
post-ICU
P value All
patients
(n = 36)
Status 6 months
post-ICU
P value All
patients
(n = 15)
Status 6 months
post-ICU
P value
Alive (n = 28) Dead
(n = 23)
Alive
(n = 22)
Dead
(n = 14)
Alive
(n = 6)
Dead
(n = 9)
0.03 0.01 0.53
1 17 (33) 11 (21) 6 (12) 9 (25) 7 (32) 2 (14) 8 (53) 4 (67) 4 (44)
2 13 (26) 10 (20) 3 (6) 11 (31) 9 (41) 2 (14) 2 (13) 1 (17) 1 (11)
3 16 (31) 6 (12) 10 (20) 12 (33) 6 (27) 6 (43) 4 (27) 0 (0) 4 (44)
4 5 (10) 1 (2) 4 (8) 4 (11) 0 (0) 4 (29) 1 (7) 1 (17) 0 (0)
Data are expressed as n (%). PRESERVE score calculation as described in Table 1. ECMO, extracorporeal membrane oxygenation; PRESERVE, Predicting Death for
Severe ARDS on VV-ECMO.
Table 7 RESP Risk Groups for all patients and according to the type of cannulation, ether veno-venous or veno-arterial
ECMO
RESP risk
group
Veno-venous and veno-arterial ECMO Veno-venous ECMO Veno-arterial ECMO
All
patients
(n = 51)
Status at hospital
discharge
P value All
patients
(n = 36)
Status at hospital
discharge
P value All
patients
(n = 15)
Status at hospital
discharge
P value
Alive
(n = 28)
Dead
(n = 23)
Alive
(n = 22)
Dead
(n = 14)
Alive
(n = 6)
Dead
(n = 9)
0.07 0.035 0.61
I 3 (6) 3 (6) 0 (0) 3 (8) 3 (8) 0 (0) 0 (0) 0 (0) 0 (0)
II 18 (35) 11 (22) 7 (14) 10 (28) 9 (25) 1 (3) 8 (53) 2 (13) 6 (39)
III 23 (45) 13 (25) 10 (20) 17 (47) 9 (25) 8 (22) 6 (39) 4 (27) 2 (13)
IV 7 (14) 2 (4) 5 (10) 6 (16) 2 (5) 4 (10) 1 (7) 0 (0) 1 (7)
V 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Data are expressed as n (%). RESP score calculation as described in Table 2. ECMO, extracorporeal membrane oxygenation; RESP (score), Respiratory Extracorporeal
membrane oxygenation Survival Prediction (score).
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with a higher tidal volume and had a lower PaCO2. This
may be ascribed to the use of BiPAP® ventilation allow-
ing spontaneous breathing in our study, while patients
were ventilated in a volume-controlled mode in the
study of Schmidt and colleagues [9].
With regards to parameters incorporated in the RESP
score [10], patients were comparable concerning PaCO2,
peak inspiratory pressure and days of mechanical venti-
lation before ECMO initiation, but patients in our study
tended be older with a higher incidence of immunocom-
promised status. Data capture concerning bicarbonate
infusion and neuromuscular blockade agents were in-
complete in our study population (complete for 18%
concerning bicarbonate and 49% concerning neuromus-
cular blockade agents), thereby influencing the score
calculation.
Overall, the PRESERVE score is easier to use, while
calculation of the RESP score (with a total of 12 different
variables) is much more complex therefore limiting its
bedside practicality.
Due to the very small number of patients that under-
went initiation of ECMO in another hospital by our mo-
bile ECMO team, we were not able to perform a
validation of the score as proposed by Roch and col-
leagues for the original setting [11]. When applying the
score to the whole study population, this score failed to
predict hospital mortality.
A striking difference between our study and that of
Schmidt and colleagues [9] is the number of patients
treated on v-a ECMO. In our study, v-a cannulation was
chosen in 29% of cases when deemed necessary because
of severe hypoxemia, hemodynamic instability and pul-
monary hypertension as assessed by echocardiography
or pulmonary artery catheterization (irrespective of signs
of moderate to severe cardiac failure). In contrast,
Schmidt and colleagues [9] applied v-a ECMO in only
5% of patients with moderate to severe cardiac depres-
sion. A similarly high percentage of v-a cannulation in
ARDS patients as in our study was reported by Hemmila
and colleagues [13] who explained it as “need for sys-
temic arterial perfusion support in addition to respira-
tory support”. Mortality rates in patients receiving v-a
cannulation are higher in our study and in the study of
Hemmila and colleagues [13] compared to v-v cannu-
lated patients, suggesting that patients in whom v-a can-
nulation is considered represent a subset of patients
with a worse prognosis. However, we cannot exclude
that v-a cannulation by itself is a predictor for poor sur-
vival of unknown origin [14].
Overall 6-month survival of all patients included in
our study was 55%. Survival for patients treated on v-v
ECMO (61%) is comparable [5,9,15] or higher [12,16]
than in previous studies. As in the studies of Schmidt
and colleagues [9,10], survivors in our study were youn-
ger, had less comorbidity and a shorter time interval be-
tween admission and ECMO initiation.
Validating the PRESERVE and RESP scores in the set-
ting of our study confirms their usefulness in discrimin-
ating survival probability for ARDS patients treated on
ECMO in a tertiary hospital (Figure 1), and particularly
in the subgroup of patients treated on v-v ECMO. Be-
cause of the small number of patients treated on v-a
ECMO no final conclusion can be drawn from the find-
ings in our study. In the subgroup of patients treated on
v-v ECMO we found an AUC of 0.75 (95% CI 0.57 to
0.92) using the PRESERVE score and an AUC of 0.81
Table 8 Roch Score for all patients and patients retrieved by mobile ECMO team only
Roch
score
All patients
(n = 51)
Status at hospital discharge P value Externally retrieved
patients (n = 6)
Status at hospital discharge P value
Alive (n = 29) Dead (n = 22) Alive (n =3) Dead (n =3)
0.57 0.2
0-2 22 (43) 14 (27) 8 (16) 2 (33) 2 (33) 0 (0)
3-4 29 (57) 15 (29) 14 (27) 4 (66) 1 (17) 3 (50)
Data are expressed as n (%). Roch score calculation as described in Table 3. ECMO, extracorporeal membrane oxygenation.
Table 9 ROC Analysis of the PRESERVE score, RESP score and the score published by Roch and colleagues
Score Original publication All patients (n = 51) v-v ECMO (n = 36)
AUC 95% CI AUC 95% CI AUC 95% CI
PRESERVE 0.89 0.83-0.94 0.67 0.52-0.82 0.75 0.57-0.92
RESP 0.74 0.72-0.76 0.65 0.5-0.8 0.81 0.67-0.95
with PRESERVE population 0.92 0.89-0.97
All patients (n = 51)
Roch 0.802 0.71-0.89 0.55 0.38-0.71
AUC, area under the curve; PRESERVE, Predicting Death for Severe ARDS on VV-ECMO; RESP (score), Respiratory Extracorporeal membrane oxygenation Survival
Prediction (score); ROC, receiver operating curve; v-v ECMO, veno-venous extracorporeal membrane oxygenation.
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(95% CI 0.67 to 0.95) with the RESP score, compared to
0.89 (95% CI 0.83 to 0.94) in the PRESERVE study [9]
and 0.74 (95% CI 0.72 to 0.76) in the RESP study [10].
The lower AUC of the PRESERVE score in our study
suggests a weaker but significant performance for the
PRESERVE score if applied externally, which is not the
case for the RESP score. While there is good agreement
of mortality risk estimation in PRESERVE score groups
2 and 3, the overall survival in group 1 in our study was
lower than in the French study (78% versus 97%). In
contrast, mortality risk estimation obtained using the
RESP score is much closer to what we observed. This
difference between PRESERVE mortality risk estimation
and observed mortality may be explained by the high
mortality in the subgroup of patients treated with v-a
ECMO (60%) in our study, again suggesting that, com-
pared to v-v cannulation, v-a cannulation is an unfa-
vorable prognostic factor. The slightly higher Charlson’s
comorbidity index in our patients may also contribute to
the higher mortality. While the PRESERVE score is
Table 10 Survival according to the PRESERVE, RESP and Roch scores
Score Group Score Original publication All patients (n = 51) v-v ECMO (n = 36) v-a ECMO (n = 15)
PRESERVE 1 0-2 97 65 78 50
2 3-4 79 77 82 50
3 5-6 54 38 50 0
4 ≥7 16 20 0 100
RESP I ≥6 92 100 100 -
II 3-5 76 61 90 25
III −1 to 2 57 56 53 30
IV −5 to −2 33 29 33 0
V ≤–6 18 - - -
All patients (n = 51) Mobile ECMO (n = 6)
Roch - 0-2 60 64 100 -
- 3-4 7 50 25 -
Results are shown as %. PRESERVE, Predicting Death for Severe ARDS on VV-ECMO; RESP (score), Respiratory Extracorporeal membrane oxygenation Survival
Prediction (score); v-v ECMO, veno-venous extracorporeal membrane oxygenation; v-a ECMO, veno-arterial extracorporeal membrane oxygenation.
Figure 1 Kaplan-Meier estimates of cumulative probabilities of 6-month survival for patients in PRESERVE groups 1 (0-2 points, n = 17),
2 (3-4 points, n = 13), 3 (5-6 points, n = 16) and 4 (≥7 points, n = 5). ECMO, extracorporeal membrane oxygenation; PRESERVE, Predicting
Death for Severe ARDS on VV-ECMO.
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validated for use in ARDS patients through our findings,
it showed suboptimal performance in a heterogeneous
collective of patients treated on v-v ECMO for acute
respiratory failure [17].
Recently, another publication [7] assessed the risk of
unsuccessful ECMO treatment in severe ARDS patients.
Based on the Italian national referral network set up by
the health care authorities to face the H1N1 epidemic in
2009, the ECMOnet score has been created [7]. Length
of stay in hospital and extra-pulmonary organ function
before ECMO support were significant independent pre-
dictors of death.
Available study data [7,9,10], as well as the findings in
our study, suggest that pulmonary infection (viral or
bacterial), asthma, direct non-bacterial lung injury
(trauma, burn, aspiration) and duration of mechanical
ventilation <48 hours are predictors of a successful
ECMO treatment in acute severe respiratory failure. In
contrast, mechanical ventilation prior to ECMO treat-
ment for more than 5 to 7 days, a non-pulmonary cause
of ARDS, chronic lung disease, high PaCO2 (≥75 mmHg)
and an elevated peak inspiratory pressure (>35 cmH2O)
are independent predictors for poor ECMO treatment
outcome characterizing the state of lung disease. Among
non-pulmonary risk factors for poor outcome, older age
(>60 years), immunocompromised status, central ner-
vous system dysfunction, cardiac arrest before ECMO
and SOFA score >12 were identified.
A limitation of our study is the retrospective design and
the relatively small number of patients included, limiting
the statistical power of the analysis. The high percentage
of v-a cannulated patients in our study may have intro-
duced an additional external confounder influencing our
validation of the PRESERVE score. Due to the differences
in cannulation modus and characteristics/outcomes in v-a
and v-v cannulated ARDS patients, this topic should be
addressed in further studies to identify factors guiding the
choice of cannulation mode in these patients. Likewise,
further characterization of patients with a low survival rate
(PRESERVE group 4) would be valuable to guide decision
finding before ECMO implantation.
Conclusion
In conclusion, our study results validate the PRESERVE
and RESP scores as a useful tool for risk stratification in
patients suffering from severe ARDS considered for
ECMO therapy. While the ECMOnet score [7] is more
limited to the H1N1 experience, the PRESERVE score [9]
and the RESP score [10] are valuable options for risk as-
sessment in patients with severe respiratory failure. Since
ECMO therapy is a highly invasive and costly therapy
where optimal conditions for patient selection are re-
quired, this is an important finding for further improve-
ment in stratification of mortality risk in these patients.
Key messages
 The PRESERVE and RESP scores prove useful in
this external validation.
 This is an important finding for further stratification
of mortality risk for ECMO treatment in severe
ARDS.
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